- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 870087-36-8] Apilimodmesylate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-14644A |
| Brand: | MCE |
| CAS: | 870087-36-8 |
Overview
| MDL | MFCD28167749 |
|---|---|
| Molecular Weight | 610.70 |
| Molecular Formula | C25H34N6O8S2 |
| SMILES | CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC4=CC=CC=N4)=N2)=C1.CS(=O)(O)=O.CS(=O)(O)=O |
12 Publications Citing Use of MCE
- [1]Sci Adv. 2022 Jul 22;8(29):eabn1440.
- [2]Nat Commun. 2020 Mar 27;11(1):1620.
- [3]Biomaterials. 2022 Jun;285:121509.
- [4]Theranostics. 2020 Mar 4;10(9):3925-3938.
- [5]Cell Mol Life Sci. 2016 Dec;73(24):4717-4737.
- [6]Br J Cancer. 2020 Aug;123(4):542-555.
- [7]J Virol. 2021 Aug 18;JVI0097521.
- [8]J Biol Chem. 2022 Dec 6;102775.
- [9]Commun Biol. 2022 Mar 24;5(1):262.
- [10]Biotechnol J. 2022 Dec 7;e2200147.
- [11]Viruses. 2021 Jun 28;13(7):1255.
- [12]bioRxiv. 2020 Apr 21;2020.04.21.053058.
Summary
IC50 & Target
|
IL-12
|
IL-23
|
In Vitro
Apilimod inhibits IFN-γ production induced by either IFN-γ/SAC or SAC in human PBMCs, with an IC 50 of approximately 20 nM. Apilimod show some inhibition against IFN-γ/SAC-induced TNF-α and ConA-induced IL-5 from human PBMCs at high concentrations, but no suppressive effect against IL-1β, IL-2, IL-4, IL-8, and IL-18 in all cultures tested. The p35 and p40 promoter-driven luciferase activities are significantly induced after stimulation with IFN-γ/LPS or IFN-γ/SAC, and are completely suppressed by 100 nM Apilimod [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Apilimod (10 mg/kg, p.o.) is effective not only when administered throughout the entire experiment, but also when administration is initiated on day 30 when disease is clearly measurable but not maximal. Apilimod causes a significant reduction in cell number only in the Th1 model, with an average percentage of inhibition of 51%±8% relative to the vehicle control. Apilimod treatment has no effect in the Th2 setting [1] . Apilimod (5 or 20 mg/kg, p.o.) reduces the level of IL-12 p40 in serum without altering body weight in EAU mice. Oral administration of Apilimod reduces the severity of experimental autoimmune uveoretinitis (EAU) by clinical and histopathological analysis [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04446377 | AI Therapeutics, Inc.|Yale University |
COVID-19 Disease
|
July 15, 2020 | Phase 2 |
| NCT00642629 | Synta Pharmaceuticals Corp. |
Active, Moderate to Severe Rheumatoid Arthritis
|
December 2005 | Phase 2 |
| NCT00250198 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Crohn´s Disease
|
November 3, 2005 | Phase 2 |
| NCT00263237 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Common Variable Immunodeficiency
|
December 2, 2005 | Phase 1 |
| NCT00234741 | Synta Pharmaceuticals Corp.|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH) |
Crohn´s Disease
|
November 2005 | Phase 2 |
| NCT00138840 | Synta Pharmaceuticals Corp. |
Crohn´s Disease
|
August 2005 | Phase 2 |
| NCT00088062 | Synta Pharmaceuticals Corp. |
Crohn´s Disease
|
February 2004 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 163.75 mM ; Need ultrasonic)
DMSO : 12.5 mg/mL ( 20.47 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6375 mL | 8.1873 mL | 16.3747 mL |
| 5 mM | 0.3275 mL | 1.6375 mL | 3.2749 mL |
| 10 mM | 0.1637 mL | 0.8187 mL | 1.6375 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (163.75 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (2.05 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.25 mg/mL (2.05 mM); Clear solution
References
- [1] Wada Y, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64.
- [2] Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.IDrugs. 2007 Jan;10(1):53-9.
- [3] Keino H, et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.